Sign in
ATHE Stock Price, Chart, Stats & News
Alterity Therapeutics Limited
Save
44.42M
Market cap
–
Current P/E
–
Forward P/E
ATHE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 96.85% |
Operating margin | -519.33% |
Pretax margin | -444.49% |
Net margin | -376.05% |
Effective tax rate | 15.40% |
ROA | -25.35% |
ROE | -29.84% |
D/E | 0.00x |
Interest coverage ratio | – |
ATHE valuation
P/E | – |
P/S | 10.87x |
P/B | 1.44x |
P/CF | -6.10x |
P/FCF | -17.68x |
P/OCF | -6.10x |
PEG | -0.16x |
EV multiple | -4.57x |
About
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue